Abstract
We sought to test the hypothesis that the variable number of tandem repeat (VNTR) polymorphism in the 3′-untranslated region (3′-UTR) of the SLC6A3 gene modulates behavior in children with ADHD and/or behavioral response to methylphenidate (MPH). One hundred and fifty-nine children with AHDH (6–12 years) were assessed with regard to the Conners’ Global Index for parents (CGI-Parents) and teachers (CGI-Teachers) and the response of these behaviors to MPH (0.5 mg/kg/day) using a 2-week prospective within-subject (crossover) trial. Based on CGI-Parents, the profile of behavioral response to MPH as compared to placebo was not parallel in the three groups of children separated according to their genotype in the 3′-UTR VNTR polymorphism of SLC6A3, as indicated by a significant (p=0.017) genotype by treatment two-way interaction. Individuals having the 9/10 and 10/10 genotypes displayed a significant positive response to MPH as opposed to those homozygous for the 9-repeat allele. No genotype or genotype by treatment interaction was observed for CGI-Teachers. These findings support a role for the DAT gene 3′-UTR VNTR polymorphism in modulating the response of some behavioral dimensions to MPH in children with ADHD. They also suggest the presence of genetic heterogeneity that could be indexed by the quality of behavioral response to MPH.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
American Academy of Pediatrics (2001). Subcommittee on attention-deficit/hyperactivity disorder and committee on quality improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108: 1033–1044.
Achenbach TM (1991). The Child Behavior Checklist/4-18 and 1991 Profile. University of Vermont: Burlington, Vermont.
Biederman J, Faraone SV (2005). Attention-deficit hyperactivity disorder. Lancet 366: 237–248.
Conners CK (1997). Conners Rating Scales-Revised: Technical Manual. Multi-Helath Systems: New York.
Conners CK (1999). Rating scales for use in assessment and clinical trials with children. In: Greenhill LL and Osman BB (eds). Ritalin Theory and Practice. Mary Ann Liebert, Inc.: New York. pp 113–126.
Denney CB (2001). Stimulant effects in attention deficit hyperactivity disorder: theoretical and empirical issues. J Clin Child Psychol 30: 98–109.
Faraone SV, Biederman J, Zimmerman B (2005). Correspondence of parent and teacher reports in medication trials. Eur Child Adolesc Psychiatry 14: 20–27.
Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S (2001). The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 1: 152–156.
Greenwood TA, Alexander M, Keck PE, McElroy S, Sadovnick AD, Remick RA et al (2001). Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder. Am J Med Genet 105: 145–151.
Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG et al (2000). Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22: 133–139.
Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB et al (2000). Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 157: 1700–1703.
Joober R, Toulouse A, Benkelfat C, Lal S, Bloom D, Labelle A et al (2000). DRD3 and DAT1 genes in schizophrenia: an association study. J Psychiatr Res 34: 285–291.
Kelsoe JR, Sadovnick AD, Kristbjarnarson H, Bergesch P, Mroczkowski-Parker Z, Drennan M et al (1996). Possible locus for bipolar disorder near the dopamine transporter on chromosome 5. Am J Med Genet 67: 533–540.
Kirley A, Lowe N, Hawi Z, Mullins C, Daly G, Waldman I et al (2003). Association of the 480 Bp DAT1 allele with methylphenidate response in a sample of irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet 121: 50–54.
Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd et al (1994). DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry 151: 1673–1685.
Littell RC, Milliken GA, Stroup WW, Wolfinger RD (2005). SAS System for Mixed Models. SAS Institute Inc.: Cary, North Carolina.
Lott DC, Kim SJ, Cook Jr EH, de WH (2005). Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 30: 602–609.
Martin N, Scourfield J, McGuffin P (2002). Observer effects and heritability of childhood attention-deficit hyperactivity disorder symptoms. Br J Psychiatry 180: 260–265.
Martinez D, Gelernter J, bi-Dargham A, van Dyck CH, Kegeles L, Innis RB et al (2001). The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24: 553–560.
Masellis M, Basile VS, Muglia P, Ozdemir V, Macciardi FM, Kennedy JL (2002). Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder. Behav Brain Res 130: 85–90.
McGough JJ (2005). Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 57: 1367–1373.
Mill J, Asherson P, Browes C, D’Souza U, Craig I (2002). Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 114: 975–979.
Miller GM, Madras BK (2002). Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 7: 44–55.
National Institute of Mental Health (1998). NIMH DISC-IV. Joy and William Ruane Center to Identify and Treat Mood Disorders, Columbia University.
Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH (2002). Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 12: 497–499.
Schachter HM, Pham B, King J, Langford S, Moher D (2001). How efficacious and Safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Can Med Assoc J 165: 1475–1488.
Senn S (2002). Cross-over Trials in Clinical Research. John Wiley: New York.
Sherman DK, McGue MK, Iacono WG (1997). Twin concordance for attention deficit hyperactivity disorder: a comparison of teachers' and mothers’ reports. Am J Psychiatry 154: 532–535.
Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C et al (2005). Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30: 1374–1382.
Stein MT (2004). When parents and teachers disagree about a child's behavior: an opportunity for further evaluations. J Dev Behav Pediatr 25: 50–51.
Terwilliger JD, Haghighi F, Hiekkalinna TS, Goring HH (2002). A biased assessment of the use of SNPs in human complex traits. Curr Opin Genet Dev 12: 726–734.
van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M et al (2005). Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 46: 745–751.
Waldman ID, Robinson BF, Feigon SA (1997). Linkage disequilibrium between the dopamine transporter gene (DAT1) and bipolar disorder: extending the transmission disequilibrium test (TDT) to examine genetic heterogeneity. Genet Epidemiol 14: 699–704.
Winsberg BG, Comings DE (1999). Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 38: 1474–1477.
Acknowledgements
This work was supported in part by a grant from the Fond de Recherche de Santé du Québec and the Canadian Institutes of Health Research to RJ and NG. We thank Chawki Benkelfat and Ashok Malla for their comments, Rosherrie Deguzman, Johanne Bellingham, Nicole Pawliuk and Anna Polotskaia for technical and clinical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Joober, R., Grizenko, N., Sengupta, S. et al. Dopamine Transporter 3′-UTR VNTR Genotype and ADHD: a Pharmaco-Behavioural Genetic Study with Methylphenidate. Neuropsychopharmacol 32, 1370–1376 (2007). https://doi.org/10.1038/sj.npp.1301240
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301240
Keywords
This article is cited by
-
Potential for diagnosis versus therapy monitoring of attention deficit hyperactivity disorder: a new epigenetic biomarker interacting with both genotype and auto-immunity
European Child & Adolescent Psychiatry (2018)
-
Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder
The Pharmacogenomics Journal (2017)
-
Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD
The Pharmacogenomics Journal (2014)
-
The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD
BMC Psychiatry (2010)
-
Response to methylphenidate is not influenced by DAT1 polymorphisms in a sample of Brazilian adult patients with ADHD
Journal of Neural Transmission (2010)
